follow-up evaluation of a patient with hematologic malignancy.
Case Report
An Asian female in her late 30s with no past medical history was diagnosed with chronic myeloid leukemia (CML) by leukocytosis with a periodic health examination. Initial treatment using imatinib (Gleevec) did not result in a major molecular response, 8 so the decision was made to begin treatment using nilotinib (Tasigna) due to the patient's desire to have children. Unfortunately, severe side effects warranted alteration in treatment strategy, and the patient was placed on dasatinib (Sprycel) at the recommended dose (100 mg/d). After five months of dasatinib treatment, a major molecular response was attained, and the treatment regimen continued until approximately 30 months when the patient complained of dyspnea on effort. A chest radiograph (CXR) revealed bilateral pleural effusion, which is considered to be a known adverse effect of dasatinib. In spite of being placed on diuretic therapy (furosemide [Lasix ® ] 20 mg/d), the patient's symptoms became more profound over the course of the next 2 months, developing orthopnea, signs of mild hepatomegaly, lower limb edema, weight gain of 7 kg, and a decrease in right lung sounds.
On admission, the patient's blood pressure was 102/64 mmHg, sinus rhythm with rate of 80 beats/min, and oxygen saturation was 96% in room air. The CXR revealed prominent bilateral pulmonary arteries, pleural effusion, and cardiomegaly ( Figure 1b ). The electrocardiogram (ECG) exhibited right-axis deviation, T-wave inversion in the right precordial leads, and deep S waves in the lateral precordial leads, suggesting a right heart overload ( Figure 1e ). Blood tests revealed elevated brain natriuretic peptide (291.3 pg/ml), glutamic oxaloacetic transaminase (56 IU/l), lactate dehydrogenase (380 IU/l), creatinine (0.95 mg/dl), and white blood cell count (13 480/ml, with a lymphocyte fraction of 67.7%), indicating lymphocytosis. Arterial blood gases were within normal limits. A contrast-enhanced computerized tomography scan of the chest, abdomen, and lower extremities demonstrated moderate bilateral pleural effusion, pericardial effusion, and dilatation of the pulmonary trunk (34 mm), but no signs of pulmonary thromboembolism, parenchymal lung involvement, or deep vein thrombosis were found. Furthermore, no sign of pulmonary thromboembolism was found on lung perfusion scintigraphy. Other specific etiologies of PAH were excluded, including portal hypertension, human immunodeficiency virus infection, congenital heart disease, connective tissue diseases, and left heart diseases. Table 1 shows the results of transthoracic echocardiography (TTE) obtained by a CX50 system with a S5-1 transducer (Philips Medical Systems, Andover, MA). Echocardiography showed a dilated right ventricle and atrium with a significant ventricular septal flattening in both the diastolic and systolic phase, suggesting right heart pressure overload (Figures 2a, 2b , and 2c). Tricuspid annular plane systolic excursion (TAPSE, 15 mm), fractional area change (FAC, 23%), and transtricuspid E/A ratio (0.32) were all below normal parameters, suggesting severely depressed right ventricular systolic and diastolic function. There was mild tricuspid regurgitation (TR) without structural abnormality of the tricuspid valve, and the estimated mean pulmonary artery pressure (PAP) and systolic PAP were 43 mmHg and 72 mmHg, respectively. Systolic PAP was estimated by adding the right atrial pressure (RAP) to the peak TR-pressure gradient. Right atrial pressure was estimated from the diameter of the inferior vena cava and the presence of inspiratory collapse. 9 Mean PAP was estimated using the following equation: mean PAP = 1/3 × systolic PAP + 2/3 × diastolic PAP. 9 Elevation of mean PAP was confirmed with another formula: mean PAP = 4 × (early PR velocity) 2 + estimated RAP 9 ; this resulted in mean PAP = 42 mmHg. Left ventricular systolic function was normal, with no regional wall motion abnormality (Table 1) . Averaged E/e′ (5.4) and maximal left atrial volume index (24 ml/m 2 ) were normal, whereas septal e′ was only 7.6 cm/s due to a right ventricular contribution to the septal velocity signals. 10 The mitral E/A ratio (0.81) was also lower than normal values, indicating an impaired relaxation mitral filling pattern because of reduced left ventricular filling rather than diastolic dysfunction. 10 Although there was moderate pericardial effusion, the respiratory variations in transmitral and transtricuspid flow were 13% and 21%, respectively, suggesting no cardiac tamponade. Despite elevated pulmonary artery pressures and presence of pericardial effusion, the patient declined right heart catheterization.
Pulmonary arterial hypertension possibly related to dasatinib therapy was diagnosed, and dasatinib was permanently discontinued; furosemide treatment was increased to 40 mg, and spironolactone treatment (25 mg) was started. Symptoms rapidly improved to World Health Organization functional class I. Follow-up TTE 1 week after dasatinib discontinuation showed decreased mean and systolic PAP ( Table 1) . Pulmonary vascular resistance (PVR) was 4.0 WU, as estimated by PVR = (mPAP echo − PAWP) / CO echo , 11 where mPAP echo was the mean PAP, PAWP the pulmonary artery wedge pressure (estimated as 10 mmHg), 11 and CO echo the cardiac output. Two months after discontinuing dasatinib, all echocardiographic parameters were normal (Table 1 and Figure 3) , and CXR and ECG data were almost restored to baseline (Figure 1) ; these results were consistent with our diagnosis of dasatinib-induced PAH. Later, imatinib was started again, and the patient remained stable.
Discussion
Dasatinib, a therapeutic agent developed for CML and Ph+ acute lymphocytic leukemia (ALL), has recently been reported to induce pulmonary parenchymal changes, pleural effusion, and PAH. 5, 6, [12] [13] [14] [15] According to the French pulmonary hypertension registry, the lowest estimated incidence of PAH occurring in patients exposed to dasatinib was 0.45%, whereas no incidental cases of PAH have been reported among patients on imatinib or nilotinib. 6 The mechanism of dasatinib-induced PAH is currently unclear. Although both imatinib and dasatinib inhibit the platelet-derived growth factor (PDGF) receptor pathway, imatinib has been shown to improve PAH, whereas dasatinib can induce PAH. 5, 6, [12] [13] [14] [15] Dasatinib exhibits a broader spectrum of TK inhibition than other clinical TKIs, such as imatinib and nilotinib. 16 The main difference in the inhibitory profile between dasatinib and other TKIs is the additional inhibition of Src kinases. 16 These are crucial for smooth muscle cell proliferation and vasoconstriction. Inhibition of Src kinases, which degrade activated PDGF receptors, can increase the signaling of PDGF and other growth factors. 17 Thus, dasatinib-associated PAH may result from Src-kinase inhibition and the resultant overactivation of growth factor signaling pathways in the vasculature.
In a previous case series, the median delay between the initiation of dasatinib and a diagnosis of PAH was 34 months (range, 8-48 months). 6 In line with this, our patient developed PAH 30 months after the initiation of dasatinib. Although the patient presented with significant PAH and moderate pericardial effusion, her vital signs were stable, and there was no indication of cardiac tamponade, suggesting slow progression of PAH. 
